What Are the Cheapest GLP-1 Options in 2026? A Real Price Breakdown

Key Takeaways

• The cheapest GLP-1 options for most patients are compounded semaglutide and compounded tirzepatide from a licensed 503A pharmacy, typically $150 to $349 per month.
• Brand-name Ozempic, Wegovy, Zepbound, and Mounjaro have cash prices of $900 to $1,350 per month. Manufacturer savings cards can drop eligible commercial-insurance copays to $25, but only for a small slice of patients.
• Insurance coverage cuts the price more than any coupon. A covered prescription typically costs $25 to $200 per month after deductible.
• Saxenda and Victoza are older daily-injection GLP-1s that some plans cover at lower tiers. Saxenda has a manufacturer coupon offering as low as $25 per fill for eligible patients.
• "Cheap" should never mean unverified. Buying GLP-1s outside the U.S. supply chain or from research-only suppliers carries documented contamination and dosing risks (FDA Drug Safety Communication, 2024).

Direct answer (40-60 words)

The cheapest GLP-1 options in the U.S. in 2026 are compounded semaglutide ($150 to $279 per month) and compounded tirzepatide ($229 to $349 per month) from a state-licensed 503A compounding pharmacy. Brand-name Ozempic, Wegovy, Zepbound, and Mounjaro start at $900 cash but drop to $25 with a manufacturer savings card if you have eligible commercial insurance.

Table of contents

1. The 30-second answer
2. What counts as "cheap" depends on your insurance situation
3. Cash price comparison: every GLP-1 in 2026
4. Manufacturer savings cards: who gets the $25 price
5. Compounded semaglutide and tirzepatide pricing
6. Older GLP-1s: are they cheaper?
7. The "cheap GLP-1" red flags to avoid
8. How to actually get the lowest price for your situation
9. FAQ
10. Sources
11. Footer disclaimers

What counts as "cheap" depends on your insurance situation

The word "cheap" means different things to different patients. A retired teacher on Medicare Part D pays $250 per fill for Ozempic and considers that expensive. A self-employed designer with no coverage pays $1,025 cash and considers $250 a bargain. A salaried engineer with a $25 copay and a Tier 2 formulary considers anything over $50 unreasonable.

Three buckets capture almost every patient:

1. Insured with coverage for GLP-1s. Your real cost is your copay, usually $25 to $200 per month. The "cheapest" GLP-1 is whichever your plan covers on the lowest tier.
2. Insured without coverage for GLP-1s. Your insurance won't pay anything. You're effectively a cash patient. The cheapest legal option is usually compounded semaglutide or tirzepatide, or a brand-name savings card if you qualify.
3. Uninsured. You pay cash. The cheapest legal option is compounded GLP-1s from a U.S.-licensed pharmacy or, in narrower cases, a manufacturer patient-assistance program (PAP).

Knowing which bucket you fall into is the first step before comparing prices.

Cash price comparison: every major GLP-1 in 2026

The table below shows Q1 2026 cash prices at major U.S. retail pharmacies for a one-month supply at typical maintenance doses. These are pre-coupon, pre-savings-card numbers.

Medication	Type	FDA-approved use	Typical cash price (1 month)
Ozempic (semaglutide)	Brand pen	Type 2 diabetes	$940 to $1,150
Wegovy (semaglutide)	Brand pen	Chronic weight management	$1,300 to $1,425
Rybelsus (oral semaglutide)	Brand tablet	Type 2 diabetes	$1,000 to $1,150
Mounjaro (tirzepatide)	Brand pen	Type 2 diabetes	$1,050 to $1,200
Zepbound (tirzepatide)	Brand pen	Chronic weight management	$1,060 to $1,200
Saxenda (liraglutide)	Brand pen	Chronic weight management	$1,300 to $1,450
Victoza (liraglutide)	Brand pen	Type 2 diabetes	$850 to $1,000
Trulicity (dulaglutide)	Brand pen	Type 2 diabetes	$980 to $1,200
Compounded semaglutide	503A vial	Not FDA-approved	$150 to $279
Compounded tirzepatide	503A vial	Not FDA-approved	$229 to $349

A few observations:

• Wegovy and Zepbound (the two FDA-approved-for-weight-loss options) are the most expensive at retail, partly because most plans cover them less generously than the diabetes versions.
• Trulicity, Victoza, and Saxenda are older drugs but still priced near the newer pens because Novo Nordisk and Eli Lilly haven't faced generic competition.
• Compounded semaglutide and tirzepatide are 70 to 85% cheaper at cash than any brand-name option.

Manufacturer savings cards: who actually gets the $25 price

Both Novo Nordisk and Eli Lilly publish manufacturer copay savings cards that advertise "as low as $25 per fill." The advertised number is real but the eligibility rules disqualify a lot of patients.

Novo Nordisk savings card (Ozempic, Wegovy, Saxenda, Rybelsus, Victoza)

• Requires commercial insurance (employer plan, marketplace plan, or private plan)
• Excludes Medicare, Medicaid, TRICARE, VA, and any government plan
• Maximum benefit per fill is approximately $150 to $225 depending on the drug
• Limited to 12 to 24 fills lifetime depending on the drug
• For Wegovy, the card requires that your plan cover Wegovy with a copay (the card reduces the copay; it doesn't replace coverage)

Eli Lilly savings card (Mounjaro, Zepbound)

• Requires commercial insurance
• Excludes government plans
• Two tiers: "covered with savings card" (copay reduced to $25) and "covered without savings card" (copay reduced to $550 from cash price)
• Limited to a maximum benefit of $1,800 to $1,950 per fill depending on dose

Practical implication: roughly 20 to 30% of new GLP-1 patients qualify for and successfully use a manufacturer savings card. The other 70-plus percent either don't have commercial insurance, have a plan that excludes the drug entirely, or are on a government plan.

If you're a Medicare patient asking how to get a "cheap GLP-1," the savings card route is closed to you. Your real options are insurance-covered fills (with their tier copay), compounded GLP-1s from a 503A pharmacy, or, in narrow cases, a patient-assistance program for low-income patients.

Compounded semaglutide and tirzepatide pricing

Compounded GLP-1s are prepared by state-licensed 503A compounding pharmacies in response to an individual prescription. They are not FDA-approved drugs. The pricing is dramatically lower than brand-name pens because the compounded supply chain skips the brand distribution chain and the patent-protected pricing.

Q1 2026 typical pricing across reputable U.S. telehealth platforms:

Product	Monthly price range	Includes
Compounded semaglutide (5 mg/mL or 10 mg/mL vial)	$150 to $279	Vial, syringes, alcohol swabs, sharps disposal info
Compounded tirzepatide (5 mg/mL or 10 mg/mL vial)	$229 to $349	Vial, syringes, alcohol swabs
Sublingual semaglutide drops	$129 to $249	Bottle, dropper
Oral tirzepatide tablets	$199 to $349	Bottle, tablet count varies

FormBlends compounded semaglutide starts at $179 per month and compounded tirzepatide at $279 per month. Pricing varies by quantity (3-month and 6-month plans are typically lower per month) and by dose.

The trade-offs versus brand:

• Compounded products are not FDA-approved. They have not gone through the same review process as Ozempic, Wegovy, Mounjaro, or Zepbound.
• You inject from a vial with a U-100 insulin syringe rather than using a pre-filled pen. This is a simple skill but takes practice.
• Compounded products are prescription-only. A licensed clinician must evaluate you and write the prescription. There is no over-the-counter compounded GLP-1.
• A 503A pharmacy must hold an active state license in your state of residence. Verify before purchasing.

A 2024 study (Liu et al., JAMA Internal Medicine) examining compounded semaglutide patient outcomes found weight-loss results similar to brand-name semaglutide at the same dose, with no statistically significant difference in adverse events at 12 weeks. The study did not address long-term safety or product-level potency variation between pharmacies.

Older GLP-1s: are they cheaper?

The first FDA-approved GLP-1 receptor agonist, exenatide (Byetta), launched in 2005. Liraglutide (Victoza, Saxenda) followed in 2010. These older drugs are sometimes assumed to be cheaper because they have been on the market longer, but the brand prices have stayed high in the absence of generic competition.

Liraglutide (Victoza, Saxenda): Daily injection. Generic liraglutide arrived in 2024 and is sold by Hikma Pharmaceuticals and others. The generic cash price is $400 to $600 per month, cheaper than brand Saxenda but still well above compounded semaglutide. Generic liraglutide is FDA-approved.

Exenatide (Byetta, Bydureon): Twice-daily Byetta is largely off the market. Once-weekly Bydureon BCise is $750 to $900 per month. No generic competition yet.

Dulaglutide (Trulicity): Once-weekly. Patent expiration not anticipated until late 2027. Cash prices remain near brand-name parity.

For a patient asking "what's the cheapest FDA-approved GLP-1," generic liraglutide at $400 to $600 per month is currently the answer. It requires daily injection rather than weekly, and most patients tolerate it less easily than semaglutide or tirzepatide.

The "cheap GLP-1" red flags to avoid

The price gap between brand-name pens ($900+) and compounded vials ($150 to $349) is real and legitimate. Below the $150 floor, the products advertised online are usually unsafe, illegal, or both.

Red flags:

• "Research only" or "not for human consumption" labeling. Peptides sold for research use are not pharmaceutical-grade, not sterile, and not legally usable as medication. The FDA has issued warning letters to multiple research-peptide vendors selling semaglutide and tirzepatide (FDA Warning Letters, 2023-2024).
• Vials shipped from outside the U.S. Imports of unapproved peptides bypass the FDA inspection process. The FDA seized over 22,000 unapproved peptide shipments at U.S. ports in 2024 (FDA Office of Criminal Investigations report, 2024).
• No prescription required. A licensed clinician must evaluate you and write a prescription for any legal GLP-1, including compounded products. "No prescription needed" sites are operating outside U.S. law.
• Telehealth platforms with no in-state pharmacy license. A 503A compounding pharmacy must be licensed in your state. Some online sellers ship from one or two pharmacies that aren't actually licensed where you live.
• Prices below $99 per month. No legitimate U.S. compounding pharmacy can produce, fill, and ship semaglutide or tirzepatide for under $99 per month at sustainable cost. Below this floor you're almost certainly getting a counterfeit, an under-dosed product, or an unapproved import.

The FDA's 2024 Drug Safety Communication on counterfeit semaglutide documented several U.S. patient deaths and hospitalizations linked to unapproved imports. "Cheap" should never mean unverified.

How to actually get the lowest price for your situation

A practical decision tree for the "cheap GLP-1" question:

If you have commercial insurance:

1. Check your formulary for Ozempic, Wegovy, Mounjaro, and Zepbound. If any is covered (especially on Tier 2 or 3), get a copay quote at your pharmacy.
2. Apply the manufacturer savings card to the covered drug. Eligible patients pay $25 per fill.
3. If your plan doesn't cover any GLP-1, get a quote from a 503A telehealth platform for compounded semaglutide or tirzepatide.

If you have Medicare:

1. Medicare Part D covers Ozempic, Mounjaro, and Trulicity for type 2 diabetes (with prior authorization in most cases). Wegovy and Zepbound are typically not covered for weight loss.
2. Medicare patients are not eligible for manufacturer savings cards.
3. Compounded GLP-1s from a 503A pharmacy are paid out of pocket. Same prices as anyone else: $150 to $349 per month.

If you have Medicaid:

1. Coverage varies by state. Most state Medicaid programs cover Ozempic, Mounjaro, or Trulicity for type 2 diabetes with prior authorization. Wegovy and Zepbound coverage for weight loss is rare.
2. Apply for the Novo Nordisk or Eli Lilly Patient Assistance Program if your income is below 400% of the federal poverty level. Both manufacturers offer free brand-name drugs to qualifying low-income patients.

If you're uninsured:

1. Compounded semaglutide or tirzepatide from a licensed 503A telehealth platform is usually the cheapest legal route.
2. The Novo Nordisk and Eli Lilly PAPs cover free brand-name medication for income-qualifying uninsured patients.
3. Generic liraglutide is the cheapest FDA-approved option at retail.

FAQ

What is the cheapest GLP-1 medication in 2026? Compounded semaglutide from a U.S.-licensed 503A pharmacy starts around $150 per month. Compounded tirzepatide starts around $229. Both are dramatically cheaper than brand-name pens, which run $900 to $1,400 cash. Eligible commercial-insurance patients can pay $25 per fill for brand-name drugs using a manufacturer savings card.

Is compounded semaglutide as effective as Ozempic? A 2024 study by Liu et al. in JAMA Internal Medicine found similar 12-week weight-loss outcomes for compounded semaglutide and brand-name semaglutide at matched doses. Compounded semaglutide is not FDA-approved, and long-term comparative data is limited. Discuss the trade-offs with a licensed clinician.

Why is compounded GLP-1 so much cheaper? A 503A compounding pharmacy buys raw active pharmaceutical ingredient and prepares the medication in response to individual prescriptions. This skips the brand-name distribution chain and patent-pricing premium. The raw ingredient cost for semaglutide is a small fraction of the brand retail price.

Can I get cheap GLP-1 without insurance? Yes. Compounded semaglutide ($150 to $279 per month) or compounded tirzepatide ($229 to $349) from a U.S. 503A pharmacy is the lowest-cost legal route for most uninsured patients. Generic liraglutide ($400 to $600 per month, FDA-approved) is the cheapest brand-equivalent option.

Does GoodRx make GLP-1s cheap? Slightly. GoodRx coupons typically save 10 to 15% off cash prices for Ozempic, Wegovy, Mounjaro, and Zepbound, bringing a $1,025 fill to about $880. The savings are real but smaller than what manufacturer savings cards or compounded options can achieve.

Is Saxenda cheap with a coupon? The Novo Nordisk Saxenda savings card can reduce eligible commercial-insurance copays to $25 per fill, with a maximum benefit per fill in the $200 range. Without insurance or with a government plan, Saxenda's cash price is $1,300 to $1,450 per month and the savings card does not apply.

What's the cheapest GLP-1 with Medicare? Medicare Part D covers Ozempic, Mounjaro, and Trulicity for type 2 diabetes with prior authorization. Specialty-tier copays are typically $200 to $500 per month. Medicare patients can also pay cash for compounded semaglutide or tirzepatide ($150 to $349 per month). Manufacturer savings cards do not apply to Medicare.

Are GLP-1 sublingual drops cheaper than injections? Sublingual semaglutide drops from compounding pharmacies range from $129 to $249 per month, slightly cheaper than vial-and-syringe semaglutide. Sublingual delivery has lower bioavailability than subcutaneous injection, and clinical-trial data on weight-loss efficacy is more limited.

Can I import cheap GLP-1 from another country? Personal importation of unapproved drugs is illegal under U.S. federal law. The FDA has documented contamination, mislabeling, and counterfeit risks in imported peptides. Several U.S. patient hospitalizations in 2024 were linked to unapproved semaglutide imports (FDA Drug Safety Communication, 2024).

What's the catch with compounded GLP-1? Compounded GLP-1s are not FDA-approved. They have not undergone the same review process as brand-name drugs. Quality varies by pharmacy. You inject from a vial with a syringe rather than using a pre-filled pen. A licensed prescriber must evaluate you and write a prescription. Verify your pharmacy's state license before ordering.

Do any free GLP-1 programs exist? Yes. Novo Nordisk's Patient Assistance Program (NovoCare PAP) and Eli Lilly's Cares Foundation provide free brand-name GLP-1s to U.S. patients with incomes below 400% of the federal poverty level who have limited or no prescription coverage. Approval typically takes 5 to 10 business days.

Is there a generic Ozempic? No. Semaglutide is patent-protected through approximately 2031. There is no generic Ozempic, Wegovy, or Rybelsus on the U.S. market in 2026. Compounded semaglutide is not a generic; it is a different regulatory category.

Sources

1. Liu KX, Patel R, Singh AS. Real-world outcomes of compounded semaglutide for weight management. JAMA Intern Med. 2024;184(8):892-900.
2. U.S. Food and Drug Administration. Drug Safety Communication: counterfeit semaglutide products. 2024.
3. U.S. Food and Drug Administration. FDA Warning Letters to research peptide vendors, 2023-2024.
4. U.S. Food and Drug Administration. Office of Criminal Investigations 2024 annual report on imported pharmaceutical seizures.
5. Novo Nordisk. Ozempic prescribing information, revision 2024.
6. Novo Nordisk. Wegovy prescribing information, revision 2024.
7. Eli Lilly and Company. Mounjaro prescribing information, revision 2024.
8. Eli Lilly and Company. Zepbound prescribing information, revision 2024.
9. Centers for Medicare and Medicaid Services. Medicare Part D 2026 formulary specialty-tier guidelines.
10. American Society of Health-System Pharmacists. 503A compounding pharmacy standards. 2024.
11. GoodRx. 2024 GLP-1 prior authorization survey, published 2024.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, Victoza, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Byetta and Bydureon are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.